These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 21743023)

  • 1. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
    J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
    Arumugam T; Ramachandran V; Logsdon CD
    J Natl Cancer Inst; 2006 Dec; 98(24):1806-18. PubMed ID: 17179482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.
    Zhou L; Qi L; Jiang L; Zhou P; Ma J; Xu X; Li P
    AAPS J; 2014 Mar; 16(2):246-57. PubMed ID: 24424498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
    Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
    BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
    Kawasaki D; Emori Y; Eta R; Iino Y; Hamano H; Yoshinaga K; Tanaka T; Takei M; Watson SA
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):883-92. PubMed ID: 17901954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of
    Wang X; Su W; Qin C; Gao R; Shao S; Xu X; Zhang Z; Gao J
    Front Biosci (Landmark Ed); 2024 Jul; 29(7):269. PubMed ID: 39082329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
    Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
    Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
    Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
    Holcomb B; Yip-Schneider MT; Matos JM; Dixon J; Kennard J; Mahomed J; Shanmugam R; Sebolt-Leopold J; Schmidt CM
    J Gastrointest Surg; 2008 Feb; 12(2):288-96. PubMed ID: 18049840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
    Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
    Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
    Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
    Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
    Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
    Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
    Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
    Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minocycline targets the NF-κB Nexus through suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer.
    Ataie-Kachoie P; Badar S; Morris DL; Pourgholami MH
    Mol Cancer Res; 2013 Oct; 11(10):1279-91. PubMed ID: 23858099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
    Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
    Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.